CoronaryAtlas logo
CoronaryAtlas
Fractalkine (CX3CL1)
Pathway / Plaque inflammation

Fractalkine (CX3CL1)

CX3CL1protein

Monocyte-adhesion molecule and platelet–leukocyte crosstalk mediator in plaque inflammation and atherothrombotic thrombus formation.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleTransmembrane chemokine mediating monocyte adhesion and platelet–leukocyte crosstalk in atherothrombosis.
Also acts inCap degradation / rupture, Platelet activation
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000006210

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
56
C — confounder / Type-II
72
A — assay feasibility
72
E — evidence strength
28
T1DI (composite)
8
Specificity differential (R−C)-16
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.015
Open Targets association (STEMI)

Literature evidence(3)